Aldeyra announces positive Phase 3 INVIGORATE-2 trial for reproxalap in allergic conjunctivitis

Aldeyra Therapeutics, Inc.

Primary endpoint met: ocular itching reduction at all 11 timepoints (p<0.0001).
Key secondary endpoint ocular redness achieved (p=0.004); tearing and total severity score also significant (p<0.0001).
Results consistent with prior trials; no safety concerns; 130 of 131 patients completed.
Reproxalap NDA for dry eye disease under FDA review with PDUFA date of November 23, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.